Invega Dose Escalation Timing
After initial titration, increase Invega doses only at intervals of 14-21 days if response is inadequate. 1
Dosing Framework
The approach to Invega (paliperidone) dose escalation differs significantly between oral and injectable formulations:
Oral Paliperidone Extended-Release
- Starting dose: 6 mg/day - therapeutically effective from day one with no initial titration required 2
- Dose range: 3-12 mg/day (maximum 12 mg/day) 2
- Escalation timing: After the initial period, wait 14-21 days between dose increases if clinical response remains inadequate 1
- Peak concentrations: Reached approximately 24 hours after dosing with a half-life of ~23 hours 2
The oral formulation's OROS delivery system provides stable plasma concentrations over 24 hours, eliminating the need for gradual titration at treatment initiation 3.
Injectable Paliperidone Palmitate (Invega Sustenna)
- Initiation regimen: 234 mg deltoid on Day 1, then 156 mg deltoid on Day 8 - this loading strategy rapidly achieves therapeutic levels without oral supplementation 4
- Maintenance dosing: Monthly injections thereafter
- Peak plasma levels: Median Tmax of 13 days, with drug release lasting up to 126 days 4
- Half-life: 25-49 days depending on dose 4
Critical caveat: The loading dose strategy for injectable paliperidone can cause severe, prolonged extrapyramidal symptoms including Parkinsonism if not carefully assessed beforehand 5. Ensure patients can tolerate antipsychotic dosing before implementing the standard loading regimen.
Key Clinical Principles
Monitor for extrapyramidal side-effects as the dose-limiting factor - increases should only occur within the limits of tolerability, particularly avoiding extrapyramidal symptoms which severely impact future medication adherence 1. In first-episode psychosis, this typically means a maximum equivalent of 4-6 mg haloperidol or 4 mg risperidone 1.
The 14-21 day interval allows adequate time to assess therapeutic response while minimizing the risk of cumulative side effects, particularly important given paliperidone's extended pharmacokinetic profile.
Do not rush dose escalation - low doses will not produce rapid effects on acute distress, but premature increases risk tolerability problems that undermine long-term treatment engagement 1.